Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cg-Bio Genomics Inc. currently has 1 pending office action in the Chemistry & Materials technology area. This action is being reviewed by 1 distinct examiner, MUKHOPADHYAY, BHASKAR, who is the busiest examiner for the company with 1 pending case. The prosecution is located within 1 distinct art unit. This shows a single active focus for the company's chemical patent efforts, requiring a strategy tailored specifically to this examiner's requirements.
Since there is only 1 pending office action, the company's success in the Chemistry & Materials field depends on effectively addressing the concerns of MUKHOPADHYAY, BHASKAR. This examiner's history and the specific standards of the 1 distinct art unit are the most critical factors for the practitioner to consider. The concentration of the portfolio into 1 distinct examiner and 1 distinct art unit simplifies the administrative process but increases the importance of this single interaction. Practitioners should focus on tailoring their arguments to the specific technical requirements of the chemical unit involved. With only 1 pending action, the company can afford to dedicate significant resources to ensuring a favorable outcome from this single examiner, as their decision will determine the immediate success of the company's current chemical patent efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MUKHOPADHYAY, BHASKAR | 1 | 28.2% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18900307 | HEALTHFUL SUPPLEMENT FOOD | MUKHOPADHYAY, BHASKAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18900307 | HEALTHFUL SUPPLEMENT FOOD | MUKHOPADHYAY, BHASKAR | — |
| Art Unit | Apps |
|---|---|
| 1792 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18900307 | HEALTHFUL SUPPLEMENT FOOD | MUKHOPADHYAY, BHASKAR | 1792 | §102 | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCg-Bio Genomics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bhaskar Mukhopadhyay has the most, with 1 of Cg-Bio Genomics Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
